<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Rearrangements involving the ALK gene define two distinct entities in the new 2008 WHO classification of lymphoid <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, i.e. ALK+ anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and a rare subset of ALK+ diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, rearrangements involving ALK and the echinoderm microtubule associated protein-like 4 (EML4) gene were described as a specific genetic alteration in about 6% of <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>We investigated the expression of EML4-ALK <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein in 51 reactive and 58 neoplastic lymphoid tissues </plain></SENT>
<SENT sid="3" pm="."><plain>EML4-ALK transcripts were detected in 3/51 (5.9%) of reactive lymphoid tissues and 12/58 (20.7%) of <z:hpo ids='HP_0002665'>lymphomas</z:hpo> of different categories, including follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Notably, none of these cases expressed the EML4-ALK fusion protein at Western blotting samples and immunohistochemistry </plain></SENT>
<SENT sid="5" pm="."><plain>These results indicate that EML4-ALK rearrangements are not specific of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NSCLC</z:e> and raise yet unsolved questions about their role in promoting human <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
</text></document>